The Pharmacy department are working closely with Regional Procurement Specialists, NHS England and Public Health to ensure that we order medicines appropriately to meet the needs of the Trust and maintain the supply chain. The Trust is closely monitoring stock levels of these medicines and additional stocks are being procured centrally by NHS England and Department of Health to make available to all NHS Trusts.

During these challenging times, Joint Drugs and Therapeutics Group are aware of the need to adapt processes for new medicine requests and changes to pathway to allow implementation at pace. With this in mind we are introducing a new fast track process providing an interim 6 month approval for new medicines or pathways for use on a cohort of patients. This involves a new simplified form and a rapid review process to support approval and implementation.

We are also aware of potential treatments for Covid-19 that are emerging globally to manage this pandemic. We are working to make these available as safely and quickly as possible. These medicines are being procured centrally by Public Health England from suppliers and will be available under a clinical trial for all NHS Trusts. We are working with Research and Development to implement these studies and make these medicines available within the Trust and therefore should not be prescribed outside of a clinical trial. In addition to clinical trials we are also working with pharmaceutical companies on novel therapies available to Covid-19 patients on a compassionate use basis.

We are working within the guidance of Department of Health and NHS England and hope to provide further information shortly. If you have any questions, please feel free to contact the formulary team on

Joint Drugs and Therapeutics Group